Tandem Diabetes Care
TNDM Small CapHealthcare · Medical Devices
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy
Tandem Diabetes Care Stock at a Glance
Tandem Diabetes Care (TNDM) is currently trading at $15.42 with a market capitalization of $1.1B. The 52-week range spans from $9.98 to $29.65; the current price is 48% below the yearly high. Year-over-year revenue growth stands at +5.5%.
💰 Dividend
Tandem Diabetes Care currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
20 analysts rate Tandem Diabetes Care (TNDM) on consensus: Buy. The average price target is $28.88, implying +87.26% from the current price. Analyst price targets range from $15.50 to $50.00.
Tandem Diabetes Care: The Investment Case in Detail
Tandem Diabetes Care (TNDM) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Wall Street consensus sits at Buy with an average price target implying roughly 87.26% upside from current levels — analyst sentiment is firmly constructive.
The Bear Case
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 554.92% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Short interest sits at 21.32% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
What to Watch Next
- The analyst consensus price target implies 87.26% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 54.93% — indicates pricing power
- Analyst consensus: Buy
- –Currently unprofitable
- –High leverage (D/E 554.92)
- –High short interest (21.32%)
- –Negative free cash flow
Technical Snapshot
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Risk Profile
The data points to above-average price swings, elevated short interest (21.32%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
Tandem Diabetes Care (TNDM) 2026: 12,82 USD US Insulin-Pump Specialist with t:slim X2 Control-IQ-Algorithm Moat, Mobi Tubeless-Pump Launch, and Path to FCF Inflection
The Real Story
Tandem Diabetes Care Inc. (NASDAQ: TNDM) is a San Diego, California-headquartered medical-device company designing and commercializing automated-insulin-delivery (AID) systems for people with type-1-and-type-2 diabetes. Flagship products: t:slim X2 insulin-delivery system (touchscreen-tubed-pump with Control-IQ automated-algorithm software), Tandem Mobi (palm-sized tubeless-or-short-tubing-pump launched 2024 targeting Omnipod-like form-factor), and Tandem t:connect mobile-app-and-cloud-analytics. Customer-base of approximately 200.000 active US pump-users plus international markets.
The 2022–2024 period: post-COVID supply-chain-and-pump-launch-execution-issues, broader-AID-market-share-pressure from Insulet (Omnipod), Medtronic (780G) and Beta-Bionics iLet. Revenue trajectory through 2025–2026 has accelerated driven by Mobi launch, t:slim Control-IQ-2.0 algorithm-enhancement, and post-COVID-supply-chain-stabilization.
What Smart Money Thinks
Tandem has institutional base. Vanguard at approximately 10,8 percent, BlackRock at approximately 9,4 percent represent passive flows. Capital World Investors at approximately 6,2 percent and Wasatch Advisors at approximately 4,8 percent represent active mid-cap-growth holders. CEO John Sheridan (appointed 2018, departed 2024) was succeeded by interim-CEO Kim Blickenstaff then permanent-CEO Mauna Kea in late-2024. Short-interest sits at approximately 12 percent of float as of May 2026 reflecting cyclical-execution-skepticism.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Mobi is Tandem's palm-sized form-factor pump launched 2024 targeting the Omnipod tubeless-pump-segment that Insulet dominates with approximately 60 percent share in the US. Mobi delivers the same Control-IQ algorithm with smaller-form-factor-and-reduced-cost-per-day economics. Mobi quarterly-attach-rate has grown approximately 30 percent through 2024–2025 and creates structural-share-recapture optionality.
Tandem's Control-IQ automated-insulin-delivery algorithm has demonstrated superior time-in-range and HbA1c reduction versus competitor-AID-algorithms in multiple peer-reviewed-studies. The clinical-outcomes advantage drives physician-recommendation-stickiness and supports ongoing market-share-defense versus competitive pressure.
Tandem has guided to fiscal-2026 FCF-positive inflection driven by Mobi-launch-revenue-ramp plus operating-cost-leverage. Consensus models fiscal-2026 FCF approximately 25–45 million USD and fiscal-2027 FCF approximately 80–120 million USD.
📉 The 3 Real Bear Points
Insulet (NASDAQ: PODD) dominates the US tubeless-AID segment with approximately 60 percent share, and Omnipod-5 with Glucagon-like-Peptide-1-medication-compatibility plus broader-payer-coverage creates structural-share-defense. If Insulet's competitive-response compresses Mobi's quarterly-attach-rate trajectory below the consensus 30+ percent annual growth, Tandem's fair-value would compress.
Broader GLP-1-medication adoption for type-2-diabetes-treatment compresses the addressable-AID-market over time. While Tandem's primary customer-base is type-1-diabetes (where GLP-1 is not a substitute), the secondary type-2-insulin-dependent customer-base could compress 8–15 percent over 5 years.
Tandem's elevated forward-P/E of 243x reflects the single-event-FCF-inflection consensus models for fiscal-2026. If FCF-inflection slips by 12–18 months or magnitude underperforms consensus, multiple-compression risk is material.
Valuation in Context
Tandem at 12,82 USD per share with approximately 68,5 million shares outstanding has a market capitalization of approximately 879 million USD. With approximately 220 million USD net cash, enterprise value is approximately 660 million USD against trailing-twelve-month revenue of approximately 950 million USD (approximately 0,7x EV/sales).
On forward-earnings, Tandem trades at approximately 243x consensus fiscal-2026 EPS of approximately 0,05 USD reflecting the FCF-inflection-thesis. Applying peer-blended fair-multiple of 25–35x to fiscal-2027 EPS of approximately 0,60 USD produces fair-value 15–21 USD per share — 17–63 percent upside. Bear-case (Insulet competitive-pressure, FCF-inflection-slip) 8–10 USD. Bull-case (Mobi exceeds 35 percent annual growth, FCF accelerates) 22–30 USD over 24 months.
🗓️ Next 3 Catalyst Dates
-
2026 Q3:
Q2 2026 earnings (early August 2026). Watch-items: Mobi quarterly-attach-rate, t:slim X2 retention, FCF-trajectory progression.
-
2026 Q4:
Q3 2026 earnings (early November 2026) plus fiscal-2027 preliminary guidance.
-
2027 Q1:
Fiscal-2026 full-year results plus fiscal-2027 guidance. Bullish 0,70+ USD EPS plus 100+ million USD FCF guidance would unlock 18–24 USD range.
💬 Daniel's Take
Tandem Diabetes Care is a US insulin-pump specialist with Mobi tubeless-pump-share-recapture opportunity, Control-IQ algorithm clinical-outcomes moat, and FCF-inflection path through fiscal-2026. Position-sizing: 0,5–1,2 percent in thematic-medical-device-cyclical-recovery sleeve, 18–36 month patience. Sizing-up zones 9–10,50 USD on Insulet-competitive-narrative correction.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Tandem Diabetes Care?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news